Publication
Regulatory effect of astragaloside Ⅰ and calycosin on a mouse model of cholestatic liver fibrosis
Objective: To identify and validate the optimal compatibility dosage of astragaloside Ⅰ (ASⅠ) and calycosin (CY) in the treatment of …
Project
Two Astragalus compounds work best at an unexpected dose ratio
Journal of Clinical Hepatology
What is it about?
Persistent obstruction of bile flow can cause inflammation, bile-duct injury and progressive liver fibrosis. Researchers investigated whether two compounds found in Astragalus membranaceus—astragaloside I and calycosin—could work together against cholestatic liver fibrosis.
A diet-induced mouse model was used to test different dose combinations. One combination, containing 3.125 mg/kg astragaloside I and 50 mg/kg calycosin, reduced liver enzymes, bile acids and bilirubin. It also reduced collagen accumulation and hydroxyproline, a marker of fibrosis.
The combination lowered the activity of genes associated with scar-forming cells, bile-duct proliferation, macrophages and inflammation. Its effects were comparable with those of total Astragalus saponins and were stronger than either compound alone for improving alkaline phosphatase and total bile acids.
A statistical model initially predicted that equal doses of 50 mg/kg for both compounds would be optimal. However, experimental validation showed that this predicted combination improved only a limited number of measurements and did not significantly reduce collagen deposition.
The lower dose of astragaloside I combined with the higher dose of calycosin therefore performed better than the mathematically predicted equal-dose combination, demonstrating why predicted drug ratios require experimental confirmation.
Why is it important?
Herbal formulations contain many interacting compounds, and increasing the dose of each component does not necessarily produce a stronger effect. Identifying effective combinations may help researchers simplify complex formulations and investigate their mechanisms more precisely. This study found that two Astragalus compounds acted effectively at a markedly unequal ratio. It also illustrates an important drug-development principle: mathematical optimisation can guide experiments, but biological validation remains essential.
The findings are limited to a chemically induced mouse model. They do not show that the combination is effective or safe in people with cholestatic liver disease. Additional studies must examine absorption, toxicity, molecular targets and performance in other models before clinical testing.
